CA
NZ
UK
AU
IND
US
Liminatus Pharma (NASDAQ:LIMN), a penny stock, shares are falling further in pre-market trading Wednesday, down 17.62% to $0.11, extending Tuesday's 8.06% regular-session decline. The move comes after the company announced Tuesday afternoon that itsBoard of Directorsapproved a 1-for-50 reverse stock split, which stockholders had …
Twist Bioscience (NASDAQ:TWST) shares are trading up 2.44% in pre-market action Wednesday to $118.93, giving back a chunk of Tuesday's decline after the stock had pushed to a near 52-week high following strong fiscal third-quarter results. The company reported revenue of $118.4 million, beating …
Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) jumped roughly 40% in premarket trading Tuesday, adding hundreds of millions of dollars in market value, after the company announced positive topline results from its Phase 3 LUCIDITY trial evaluating avexitide, an investigational GLP-1 receptor antagonist, in patients with …
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) shares are up 16% at $24.80 during extended hours ahead of the company's scheduled disclosure of primary data from its Phase 3 LUCIDITY study evaluating avexitide for post-bariatric hypoglycemia on August 18, 2026.
Cue Biopharma, Inc. (NASDAQ: CUE) shares ended the day down 19% at $27.64 after the company disclosed a widened Q2 net loss of $153.1 million, a figure heavily impacted by CUE-221 licensing fees and non-cash acquisition costs.
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) shares tumbled 26% to end the day at $0.56 after the company reported third-quarter financial results that missed the mark, posting a GAAP net loss of $0.34 per share, which was $0.09 wider than anticipated.
OmniAb, Inc. (NASDAQ: OABI) shares closed up 13% at $3.82 after the company raised its 2026 year-end cash outlook to $49 million to $53 million, up from $37 million to $41 million, following recent technology licensing and business development activity.
argenx SE (NASDAQ: ARGX) shares rallied 16% to end at $987.84 after the company reported that its Phase 3 ALKIVIA trial of Vyvgart Hytrulo for autoimmune myositis reached its primary endpoint, highlighting a statistically significant 15.4-point TIS improvement in the pooled IMNM/DM group versus …
Skye Bioscience, Inc. (NASDAQ: SKYE) announced it will merge with Redx Pharma to establish Fibrx Therapeutics, a new Nasdaq-listed entity dedicated to fibrosis and steered by Redx leadership.
Coherus BioSciences, Inc. (NASDAQ: CHRS) finalized a $55 million senior secured term loan with an August 2031Maturityto refinance higher-cost debt previously due in May 2029.
Please wait processing your request...